Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules

NCT04467346 is registered in ClinicalTrials.gov with Orphelia Pharma as lead sponsor.

NCT NCT04467346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04467346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules
Lead sponsor
Orphelia Pharma
Phase
Phase 1
Overall status
Completed
Start date
September 25, 2020
Completion date
December 17, 2021
Enrollment
36 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

therapeutic equivalency